Don Benson MD PhD
Hematologic Oncology
Professor of Medicine | Myeloma Program Director | Deputy Director | Division of Hematology Vice Chair - Faculty Development| Department if Internal Medicine The Ohio State University College of Medicine The Ohio State University Comprehensive Cancer Center
Join to view full profile
460 W 10th AveFl 5Columbus, OH 43210
Phone+1 614-293-3196
Fax+1 614-293-6176
Dr. Benson is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Care of people with myeloma | Laboratory, translational, and clinical immunotherapy research for myeloma | Medical education, teaching, and mentorship | Executive Leadership & Professional Development Coaching in medicine and health care
Education & Training
Ohio State University HospitalFellowship, Hematology and Medical Oncology, 2003 - 2006
University of Virginia Medical CenterResidency, Internal Medicine, 1999 - 2003
Northeast Ohio Medical UniversityClass of 1999
Certifications & Licensure
OH State Medical License 2003 - 2027
VA State Medical License 1999 - 2004
American Board of Internal Medicine Medical Oncology
Awards, Honors, & Recognition
- CMS Meaningful Use Stage 2 Certification EpicCare Ambulatory 2014 Certified EHR Suite, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory - Core EMR, Epic Systems Corporation, 2012, 2014, 2016-2017
- CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012
Clinical Trials
- Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia Start of enrollment: 2010 Aug 01
- Study on the Safety, Anti-tumor Activity and Pharmacology of IPH2101 Combined With Lenalidomide in Patients With Multiple Myeloma Experiencing a First or Second Relapse Start of enrollment: 2010 Sep 01
- A Phase II Trial of Panobinostat and Lenalidomide in Patients With Relapsed or Refractory Hodgkin's Lymphoma Start of enrollment: 2011 Oct 13
Publications & Presentations
PubMed
- Moving Mountains: Improving Access to Autologous Stem Cell Transplant for Vulnerable Patient Populations.Srinivas Devarakonda, Qiuhong Zhao, Suzanne Keirns, Naresh Bumma, Abdullah M Khan
Cancers. 2026-06-17 - Genomic Determinants and Clinical Outcomes of Second Primary Hematological Malignancies in Patients with B-cell Cancers.Justin Jiang, Subodh Bhatta, Joshua Galloway, Solomon Lisath, Andrew Srisuwananukorn
Transplantation and Cellular Therapy. 2026-04-24 - Reversible cerebral vasoconstriction syndrome following ciltacabtagene autoleucel therapy for relapsed multiple myeloma: a case report.Tuan L Phan, Adel Hijazi, Romi Xi, Mohamed Ridha, Tirisham V Gyang
Frontiers in Immunology. 2026-01-01
Journal Articles
- Human AML Activates the AHR Pathway to Impair NK Cell Development and FunctionLuxi Chen, Michael Zhang, Monica Williams, Steven D Scoville, Don M Benson, Michael A Caligiuri, Blood
Press Mentions
Inside Destination Medicine, an Ohio State Program That Heals Patients From Across the GlobeAugust 13th, 2025- Ohio State's Novel DHODH Inhibitor Enters First Human TrialsSeptember 16th, 2024
- Colin Powell Was Fully Vaccinated, but He Still Died from COVID Complications. How Rare Is That?October 18th, 2021
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
